Floatz logo

Avutometinib

CNS Tumor, Adult

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CNS Tumor, Adult cohort.

Asset / SponsorPhaseRating
ima950
University Hospital, Geneva
Phase 1/2CC

Same molecule, other indications

Avutometinib is also rated in:

KRAS Activating MutationDormant
BB
Indicative ·
69 / 100
View asset →
ovarian serous adenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →